Working Together to Improve Vaccine Confidence
Patients Australia and CSL Seqirus work together to centre patient experiences in conversations about vaccination. Together, we delivered a national patient insights report exploring Australians’ attitudes towards influenza vaccination. This work helps shed light on the challenges people face and supports clearer, more accessible information to guide vaccination decisions across the community.
Read the Patient Insights report here.
About CSL
CSL Seqirus is an Australian-based vaccine company that develops and manufactures influenza vaccines for use in more than 20 countries. As part of the CSL Group, the company focuses on protecting public health through research, science, and innovation that helps prevent serious infectious diseases.
Achieving Impact
In 2025, Patients Australia and CSL Seqirus collaborated on a national research project examining Australians’ attitudes towards influenza vaccination. Drawing on insights from more than 10,000 Australians, the research revealed a clear gap between intention and action, with many people planning to be vaccinated but fewer following through.
The report identified key opportunities to close this gap, including:
• Encouraging vaccination through stronger recommendations from doctors and pharmacists
• Expanding convenient access through pharmacies and workplaces
• Reinforcing the importance of annual vaccination as part of routine care
This collaboration highlights how evidence-based insights can guide communication, strengthen confidence, and improve vaccination rates across Australia.
